Twist Bioscience
TWST
212 hedge funds and large institutions have $2.92B invested in Twist Bioscience in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 101 increasing their positions, 48 reducing their positions, and 48 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 48
2.89% more ownership
Funds ownership: 103.26% → 106.15% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less call options, than puts
Call options by funds: $4.94M | Put options by funds: $5.42M
10% less funds holding
Funds holding: 236 → 212 (-24)
26% less capital invested
Capital invested by funds: $3.96B → $2.92B (-$1.04B)
44% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 48
Top Buyers
Top Sellers
TWST Hedge Fund Activity: Q1 2022 in Review
212 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q1 2022, worth a combined $2.92B — down 26% from $3.96B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TWST and 27 opened new positions — a net loss of 21 holders — while 48 trimmed existing stakes and 101 added.
The largest buyer was Fidelity Investments, adding an estimated $232M. The largest seller was Ardevora Asset Management, exiting entirely with an estimated $54.1M sold.
- 212 institutional investors held Twist Bioscience (TWST) as of Q1 2022, down from 236 in Q4 2021.
- Funds reported $2.92B of Twist Bioscience stock for Q1 2022, down 26% quarter-over-quarter.
- 27 funds opened new Twist Bioscience positions in Q1 2022 and 48 closed out, a net change of -21 holders.
- The largest Twist Bioscience buyer in Q1 2022 was Fidelity Investments, an estimated $232M added.
- The largest Twist Bioscience seller in Q1 2022 was Ardevora Asset Management, an estimated $54.1M sold.
Based on aggregated 13F filings for Q1 2022.